Payment overview · 2025
General Payments
$378.44
16 reported records · 8 companies
Healthcare provider profile · identity verified
Joseph Andrew Freeman
Allopathic & Osteopathic Physicians|Family Medicine · COVINGTON, TN · NPI 1194179101
Verified facts
What the public records show
CMS Open Payments records show Joseph Andrew Freeman received $378.44 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $171.23 | 45.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.46 | 13.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.89 | 10.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.63 | 8.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.32 | 7.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.63 | 5.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.72 | 4.7% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $17.56 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $378.44 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $130.64 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $91.76 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $77.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $42.07 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.63 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $28.32 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 106 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 145 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 190 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
190 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 568 | 170 |
| Atorvastatin Calcium | Atorvastatin Calcium | 550 | 165 |
| Gabapentin | Gabapentin | 395 | 100 |
| Omeprazole | Omeprazole | 380 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 368 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 349 | 73 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 302 | 45 |
| Prednisone | Prednisone | 247 | 150 |
| Escitalopram Oxalate | Escitalopram Oxalate | 228 | 67 |
| Lisinopril | Lisinopril | 225 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 70 |
| Losartan Potassium | Losartan Potassium | 221 | 67 |
| Furosemide | Furosemide | 216 | 82 |
| Trazodone Hcl | Trazodone Hcl | 206 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 195 | 59 |
| Mounjaro | Tirzepatide | 190 | 32 |
| Metformin Hcl | Metformin Hcl | 180 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 51 |
| Tramadol Hcl | Tramadol Hcl | 158 | 38 |
| Levofloxacin | Levofloxacin | 151 | 108 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 148 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 147 | 105 |
| Jardiance | Empagliflozin | 145 | 29 |
| Spironolactone | Spironolactone | 142 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 48 |
| Doxycycline Hyclate | Doxycycline Hyclate | 141 | 107 |
| Potassium Chloride | Potassium Chloride | 139 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 44 |
| Meloxicam | Meloxicam | 138 | 61 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 135 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 127 | 42 |
| Allopurinol | Allopurinol | 121 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 41 |
| Carvedilol | Carvedilol | 117 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 34 |
| Eliquis | Apixaban | 106 | 29 |
| Methylprednisolone | Methylprednisolone | 103 | 80 |
| Pregabalin | Pregabalin | 103 | 30 |
| Ozempic | Semaglutide | 102 | 21 |
| Cefdinir | Cefdinir | 100 | 87 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 97 | 72 |
| Montelukast Sodium | Montelukast Sodium | 93 | 25 |
| Sertraline Hcl | Sertraline Hcl | 93 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 25 |
| Methocarbamol | Methocarbamol | 89 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 21 |
| Alprazolam | Alprazolam | 85 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 85 | 23 |
| Celecoxib | Celecoxib | 84 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 21 |
| Fluconazole | Fluconazole | 69 | 41 |
| Clonazepam | Clonazepam | 68 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 58 | suppressed |
| Bumetanide | Bumetanide | 56 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 16 |
| Promethazine Hcl | Promethazine Hcl | 55 | 29 |
| Simvastatin | Simvastatin | 54 | 17 |
| Glipizide | Glipizide | 53 | 15 |
| Lamotrigine | Lamotrigine | 53 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 16 |
| Metformin Hcl Er | Metformin Hcl | 45 | 13 |
| Linzess | Linaclotide | 41 | 14 |
| Alendronate Sodium | Alendronate Sodium | 40 | 11 |
| Famotidine | Famotidine | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | 15 |
| Ondansetron Odt | Ondansetron | 40 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 15 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | 12 |
| Baclofen | Baclofen | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Estradiol | Estradiol | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | 12 |
| Meclizine Hcl | Meclizine Hcl | 35 | 19 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 15 |
| Atenolol | Atenolol | 32 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 13 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 19 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 13 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Metronidazole | Metronidazole | 22 | 19 |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Colchicine | Colchicine | 21 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Nystatin | Nystatin | 19 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 15 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 13 |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ethacrynic Acid | Ethacrynic Acid | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $378.44 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Doc Band, ELIQUIS, FARXIGA, GEMTESA, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error